Regeneron Pharmaceuticals, Inc.

Regeneron Phramaceuticals, Inc.

Tanya Teslovich Dostal

Aris I Baras

Claudia Schurmann

Jesper Gromada

Xiping Cheng

Frederick E Dewey

Goncalo Abecasis

Noura S Abul-Husn

Kavita Praveen

Yurong Xin

Giovanni Coppola

Lauren Gurski

Carmelo Romano

Ying Hu

Giusy Della Gatta

Gaurang Patel

Trikaldarshi Persaud

The disclosure provides methods of identifying a human subject as a candidate for treating or inhibiting a liver disease by inhibiting HSD17B13. The disclosure also provides methods of treating a subject who is PNPLA3 Ile148Met+ by administering an inhibitor of HSD17B13. The disclosure also provides method of detecting a PNPLA3 Ile148Met variant and functional HSD17B13 in a subject. The disclosure also provides method of identifying a subject having a protective effect against liver disease. The disclosure also provides inhibitors of HSD17B13 for use in the treatment of a liver disease.

Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation

The present disclosure provides methods of treating patients having an ophthalmic condition, methods of identifying subjects having an increased risk of developing an ophthalmic condition, methods of detecting human angiopoietin like 7 (ANGPTL7) variant nucleic acid molecules and variant polypeptides, and ANGPTL7 variant nucleic acid molecules and variant polypeptides.

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

Growing community of inventors

Tarrytown, NY, United States of America

Tanya Teslovich Dostal